RxDoctor Payments DataLook up a doctor →

Margaret Pullin

Rheumatology · Akron, OHNPI 1740809961

Payments from drug & device makers

$25,492in general payments, 2019–2025

Across 683 payments — averaging $37.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$10K
  • GSK$7K
  • AbbVie$2K
  • E.r. Squibb & Sons, L.L.C.$1K
  • UCB, Inc.$797
  • Pfizer$661
  • plus $3K from 21 others

What the payments were for

  • Consulting fees$7363%
  • Speaking & faculty fees$13,50053%
  • Travel & lodging$450%
  • Food & beverage$11,11244%
  • Education$990%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$25,492 in reported general payments places this provider in the 80th percentile of 255 rheumatology providers in Ohio.

See all rheumatology providers in Ohio

Medicare billing

Part B allowed, 2024
$855,985
Medicare patients
511
Services billed
62,861

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Humira(Cf) PenAdalimumab72$496,886
Enbrel SureclickEtanercept56$486,071
EnbrelEtanercept24$175,976
Orencia ClickjectAbatacept11$94,445
Taltz AutoinjectorIxekizumab13$87,641
OrenciaAbatacept11$63,487
ProliaDenosumab21$37,752
Hydroxychloroquine Sulfate747$24,006
Leflunomide177$12,643
MethotrexateMethotrexate Sodium561$12,585
Sulfasalazine DrSulfasalazine177$7,790
Celecoxib80$3,031
Prednisone303$2,192
Sulfasalazine59$1,982
Colchicine16$1,971

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AmgenEnbrel, Prolia$10,380$213,72845 claims
E.r. Squibb & Sons, L.L.C.Orencia$1,459$63,48711 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 255 rheumatology providers in Ohio.

Other rheumatology in Akron

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →